Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
<strong>Background<br></strong> Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improved antibody...
Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Diğer Yazarlar: | |
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
Elsevier
2023
|